AQXP vs. LBPH, SAGE, PLRX, TNGX, EOLS, YMAB, SIGA, ARCT, COGT, and PRTC
Should you be buying Aquinox Pharmaceuticals stock or one of its competitors? The main competitors of Aquinox Pharmaceuticals include Longboard Pharmaceuticals (LBPH), Sage Therapeutics (SAGE), Pliant Therapeutics (PLRX), Tango Therapeutics (TNGX), Evolus (EOLS), Y-mAbs Therapeutics (YMAB), SIGA Technologies (SIGA), Arcturus Therapeutics (ARCT), Cogent Biosciences (COGT), and PureTech Health (PRTC). These companies are all part of the "medical" sector.
Longboard Pharmaceuticals (NASDAQ:LBPH) and Aquinox Pharmaceuticals (NASDAQ:AQXP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.
63.3% of Longboard Pharmaceuticals shares are held by institutional investors. Comparatively, 71.7% of Aquinox Pharmaceuticals shares are held by institutional investors. 4.6% of Longboard Pharmaceuticals shares are held by insiders. Comparatively, 4.0% of Aquinox Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Longboard Pharmaceuticals currently has a consensus price target of $43.67, indicating a potential upside of 99.94%. Given Aquinox Pharmaceuticals' higher probable upside, equities research analysts clearly believe Longboard Pharmaceuticals is more favorable than Aquinox Pharmaceuticals.
Aquinox Pharmaceuticals received 255 more outperform votes than Longboard Pharmaceuticals when rated by MarketBeat users. However, 73.33% of users gave Longboard Pharmaceuticals an outperform vote while only 71.88% of users gave Aquinox Pharmaceuticals an outperform vote.
Aquinox Pharmaceuticals has higher revenue and earnings than Longboard Pharmaceuticals.
Longboard Pharmaceuticals' return on equity of -30.13% beat Aquinox Pharmaceuticals' return on equity.
In the previous week, Longboard Pharmaceuticals had 24 more articles in the media than Aquinox Pharmaceuticals. MarketBeat recorded 24 mentions for Longboard Pharmaceuticals and 0 mentions for Aquinox Pharmaceuticals. Aquinox Pharmaceuticals' average media sentiment score of 0.47 beat Longboard Pharmaceuticals' score of 0.00 indicating that Longboard Pharmaceuticals is being referred to more favorably in the media.
Longboard Pharmaceuticals has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Aquinox Pharmaceuticals has a beta of -7.37, suggesting that its stock price is 837% less volatile than the S&P 500.
Summary
Longboard Pharmaceuticals beats Aquinox Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Get Aquinox Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AQXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aquinox Pharmaceuticals Competitors List
Related Companies and Tools
